Professor Peter Sandercock is Chair of Medical Neurology. His research includes testing methods for the treatment and prevention of stroke in large clinical trials.
Studied Medicine at the University of Oxford, and undertook my postgraduate clinical training in Stoke-on-Trent, Manchester, Oxford and Liverpool, followed by a visiting academic fellowship at McMaster University Canada. My initial research was on the epidemiology of stroke in Oxfordshire, and in clinical trials of stroke prevention.
I set up and ran the first International Stroke Trial (IST-1), the first ‘mega-trial’ in acute ischaemic stroke from 1991-1997.19,453 patients were recruited within 48 hours of stroke onset from 467 hospitals in 37 countries. I am the Co-Chief Investigator of IST-3, the largest-ever trial of ‘clot-busting’ thrombolytic therapy for acute ischaemic stroke with 3035 patients.
My research covers treatment and prevention of stroke and seeks to identify which interventions are effective, which are not, and which are worth testing in large scale trials. I now spend much of my time either supporting fellow scientist in doing their own clinical trials, looking to improve patient care or teaching and training young researchers in how to do this type of scientific work.
In November 2014, Peter Sandercock gave a public lecture in the Medical Detectives series, entitled "Unravelling the mystery of stroke disease: the clue's in the numbers":
The main focus of my present research is to further explore the effects of intravenous thrombolytic therapy in acute ischaemic stroke in the IST-3 study and other similar trials.